Martin Bittner 𝘔𝘋 𝘋𝘗𝘩𝘪𝘭

Martin-Immanuel Bittner MD DPhil FRSA is a repeat entrepreneur in the technology-enabled healthcare space.4 He is currently the Co-Founder and CEO of an AI healthtech startup that is in stealth mode, as indicated by his LinkedIn profile.

Background and Education

Dr. Bittner graduated as a medical doctor from the University of Freiburg in Germany.1 He then went on to complete his DPhil (PhD) in Oncology as a Rhodes scholar at the University of Oxford.1 This combination of clinical and research experience has shaped his career path in healthcare innovation.

Previous Venture: Arctoris

Prior to his current stealth startup, Dr. Bittner was the co-founder and CEO of Arctoris, a biotech company he established in Oxford in 2016.12 Arctoris developed a novel drug discovery platform called Ulysses, which combines robotic automation and machine learning to accelerate the drug discovery process.23

Expertise and Vision

Dr. Bittner's expertise lies at the intersection of medicine, biotech, and artificial intelligence. His vision is to leverage technology, particularly AI and robotics, to revolutionize drug discovery and development.3 He believes that by using automation and data science, the traditionally slow and expensive process of drug discovery can be made more efficient and effective.2

Recognition and Affiliations

In recognition of his research achievements, Dr. Bittner was elected a member of the Young Academy of the German National Academy of Sciences in 2018.1 He is also an active member of several leading international cancer research organizations, including AACR, EACR, and ESTRO.1

Entrepreneurial Philosophy

Dr. Bittner emphasizes the importance of vision, creativity, and resilience as key skills for successful entrepreneurs.1 He advocates for a data-driven approach to drug discovery, believing that the combination of AI, machine learning, and robotics can lead to better, faster, and more reliable drug development processes.2